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Occurrence of Alzheimer Disease in Michigan: An Epidemiologic
Review of Rates and Risk Factors
Christine Cole Johnson, PhD*

Alzheimer disease is a progressive degenerative neurological disorder of insidious onset
characterized by the deterioration of cognitive functioning. Lillle is known about the etiology and
epidemiology ofthis condition. The only risk factor consistently associated with Alzheimer disease is
advancing age. As the population ofthe elderly continues to grow, many public agencies, including
those in Michigan, are concerned about social, personal, and financial implications and seek
estimates ofthe number ofpeople with dementia. To date, mortalily rates based on vital statistics have
been noninformative because Alzheimer disease is difficult lo diagnose clinically and has been
considered to be a nonspecific sign of aging, rarely appearing as an underlying cause of death on
death certificates. Incidence rates from 100 to 1,500 new cases per 100.000persons peryear have been
measured among older adults. Reporied prevalence ratios range from 3 to 15.3 per 100 persons aged
65 and older Prevalence estimates for Michigan indicate that an additional 49.000 to 130,000 cases
will exist in the year 2030 compared to 1980. (Henry Ford Hosp MedJ 1988:36:117-20)

A

lzheimer disease is an unremitting, progressive degenerative disorder of insidious onset characterized by memory
loss, confusion, and a variety of cognitive disorders. This incurable condition results in the deterioration of cognitive functioning and the ability for self-care. Pathologic findings include atrophy of the brain, a marked loss of neurons, neurofibrillary tangles, granulovacuolar changes, and neuritic plaques (1). No
treatment offers substantial amelioration of symptoms. Only recently have the dementias been recognized as a disease distinct
from aging.
One aim of epidemiology, as the basic science of public
health, is to determine the occurrence of a disease in a population. Such information is the first step toward the search for risk
factors and the assessment of the impact of a disease on a population. Since the aged population is increasing in Michigan and
nationwide, government agencies are attempting to address
the issues related to this disease. However, the study of the
epidemiology of Alzheimer disease is in its infancy. Consensus
diagnostic criteria have been established only recently (2,3).
The disease is a clinical diagnosis of exclusion, and the criteria
used to define cases have varied among descriptive epidemiologic studies. Risk factor studies for Alzheimer disease
have appeared in the literature only in the last ten years (4).
A task force on Alzheimer disease and related conditions was
formed in Michigan in eariy 1986. This report presents information that was gathered for the task force to assess the prevalence
and potential for prevention of Alzheimer disease in Michigan.

ever, Alzheimer disease, while considered by some to be the
fourth or fifth most common cause of death and perhaps the most
common cause among people over age 65, is not listed in the
United States vital statistics tables, not even in the extended listing of 263 causes of death (1,5). When an acute event leads to
death in a cancer victim, for instance, the cancer is appropriately
listed as an underlying cause of death. However, dementia has
been ignored, with the most common underlying cause of death
in a patient with Alzheimer disease being pneumonia and other
respiratory conditions, followed by cardiovascular-related difficulties (1,6). This inaccuracy probably results from demenfia
being considered as a nonspecific sign of aging.
Mortality data nevertheless reflect the predominant feature of
Alzheimer disease—the striking increase of disease with age.
Considering the tremendous degree of underreporting, annual
mortality rates for this disease have been reported to be 1.2 per
100,000 for persons aged 60 to 65 and a corresponding rate of
11.6 for those over age 85 (4). In 1984, Michigan's annual mortality rate for Alzheimer disease for persons aged 65 and older
was 13.2per 100,000, with corresponding rates of 14.0 for males
and 12.7 for females. These mortality data also exhibited a substantial increase with age, ranging from 2.1 per 100,000 in those
aged 60 to 64 to 24.9 for those aged 75 and older.
A life-shortening effect is usually associated with the diagnosis of Alzheimer disease (6,7). Early death associated with
this disease is most common among males, older patients, and

Descriptive Epidemiology
Mortality
Mortality data from death certificates often yield valuable epidemiologic information, particulariy for lethal diseases. How-
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Tabie 1
Prevalence of Clinically Diagnosed Alzheimer Disease:
Summary of Population Studies
Studies
Kayet al, 1964(11)
Akesson, 1969 (12)

Country
Great Britain
Sweden

Broeet al, 1976 (13)

Great Britain

Kaneko, 1975 (14)

Japan

Molsaet al, 1982 (15) Finland
Sulkava, 1982 (16)

Finland

USA (Mississippi)
Schoenberg et al.
1985 (17)
Pfefferet al, 1987(18) USA (California)
Pfefferet al, 1987 (18) USA (projection)

Age (years) Prevalence Ratio
Crileria
(cases/100)
65-14.2
60-10.7
80-13.9
65-F
5.8
75-110.9
65 +
1.9
90-116.7
45-F
0.4
85 +
6 3
65 +
3.6
85 +
14.8
40 +
0.5
80 +
7.0
65 +
15.3
80 +
35.8
()5
11.2

those in poor physical condition (7). One study reported that
74-year-old patients diagnosed with Alzheimer disease had a
life expectancy of 5.1 years versus the expected 9.6 years, while
for 60-year-old patients the life expectancy dropped from 23.1 to
7.1 years (1). However, because of improvements in mortality
for the aged through progress in medical care, people suffering
from dementia have experienced improved survival (8).

Prevalence
The prevalence ratio, the number of cases per number of persons in a given population at a specified time, is most useful in
measuring the social and economic impact of a disease. Prevalence ratios include both newly occurring and continuing disease conditions; therefore, the duration of disease before cure
or death contributes to the measure of prevalence. Aside from
differences that may exist due to variations in populations,
differences in disease criteria and diagnostic protocols can
make comparisons between studies difficult.
Age-specific prevalence rates for dementia in general or
Alzheimer disease specifically are unknown. However, despite
the problems particularly associated with dementia and the
usual caveats associated with observational studies, the reported
prevalence ratios for broad age categories from both institutional
and population surveys are fairly consistent. Conservative prevalence estimates approximate that 10% to 11% ofthe population
aged 65 and older have mild dementia of all types. Severe dementia exists in 1% of the population under age 65, in 4% to 6%
of those over age 65, and in over 15% of those past age 85
(1,7-10). These estimates are probably conservative due to a high
degree of underreporting.
The majority of persons with dementia (at least 55%) have
Alzheimer disease (10). Table 1 displays prevalence ratios from
studies designed specifically to measure Alzheimer disease
rather than all dementias combined (11-18). A recent Califomia
study, involving comprehensive diagnostic workups of subjects.
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yielded a strikingly high prevalence of Alzheimer disease:
15.3% among persons over age 65 in a retirement community
(18).
Incidence
Incidence, the measure of the number of new cases per
number of persons in a population over a specified time period,
is of most value for etiologic studies but is usually more difficult
to determine. For the dementias, incidence rates are even less
available than prevalence data. Follow-up studies of British and
Swedish elderly populations revealed incidence rates of 15 cases
per 1,000 persons per year (4,8). The only United States population-based incidence study, from Rochester, Minnesota, measured an incidence rate of 1 per 1,000 in persons over age 29 (6);
rates restricted to older age groups were not presented. Reported
incidence rates generally increase exponentially with age and
tend to be slightly higher in females. Little information exists
regarding the variation of incidence by time, race and other personal characteristics, or geography, except that dementia is reported wherever older people are studied (5,7).

Risk Factors
The only generally accepted risk factor for Alzheimer disease
is age, even within the elderly subgroup (1). Considering the
conditions presenile dementia and senile dementia together as
Alzheimer disease, as most investigators now regard them, the
disease is rare before age 65 but becomes increasingly more
common as age advances (5).
Only one study, in Mississippi, has systematically measured
the prevalence of Alzheimer disease in a biracial population (17).
For either sex. blacks unexpectedly had somewhat higher population prevalence ratios. Additionally, Alzheimer disease represented a higher proportion of all dementias in blacks compared
to whites (6).
Other factors which have been suggested to be associated with
Alzheimer disease are head injury, prior thyroid disease, and
familial occurrence of dementia and the Down syndrome
(2,7,19). A weak association with female gender has been suggested (7). Etiologic hypotheses have included associations with
disorders of the immune system, slow viral infections, and toxic
reactions to aluminum (20). However, no associations have been
detected to date with toxic, environmental, or occupational exposures, animal contacts, socioeconomic status, tobacco, alcohol, diet, or diseases with altered immune responses (2,7). Diagnostic difficulties and the problems associated with people
who are poor historians impede the collection of data and are
considerations that must be addressed in future epidemiologic
studies.

Prevalence of Alzheimer Disease in Michigan
One of the charges to the Michigan Task Force on Alzheimer's
Disease and Related Conditions was to estimate the present
and future magnitude ofthis condition in Michigan. Since Alzheimer disease is neither a reportable or registered disease, nor
reliably listed on death certificates, prevalence estimates can be
best obtained by applying prevalence ratios reported in study
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populations to the population projections for Michigan for the
elderly age groups.
Table 2 presents the predicted number of Alzheimer disease
cases in Michigan from 1980 to 2040. A conservative estimate of
4.2 cases per 100 persons aged 65 and older (11) and the most
recently reported prevalence projection of 11.2 (18) were used to
calculate a range for the estimated number of cases. The same
information for each county in Michigan is available from the
author upon request.

Discussion
No one knows if the incidence of Alzheimer disease is increasing. Even the most basic descriptive statistics of this disease are difficult to obtain due to 1) the lack of mention of th6
condition on death certificates, and 2) a scarcity of studies that
have systematically ascertained cases within a defined population. Reliable mortality rates would become available if Alzheimer disease was consistently listed on death certificates as the
underiying cause of death; however, the validity of these rates
would depend on the accuracy of diagnosis, which at this time is
made definitive only through postmortem examination.
Mortality rates, incidence rates, and prevalence ratios could
be determined through the eventual establishment of a population-based surveillance system or registry for Alzheimer
disease, similarto programs that assess the occurrence of reportable infectious diseases or to cancer registries. Such systems
could be developed on a regional or statewide basis and await the
development of screening tools or markers that could be used to
survey large populations.
Even ifthe incidence of Alzheimer disease is static, three factors will contribute to an inevitable epidemic of dementia in
Michigan as well as nationwide, barring the discovery of preventive or curative measures. The first factor is based simply on
demographics: due to previous birth rates and overall declines in
mortality, an increasingly larger percentage of the population in
Michigan will be over age 65 in the next decades. The US census
projects that the proportion of the population aged 65 and older
will increase from 11.2% in 1980 to 15,5% in 2020, and there is
no reason to believe that Michigan's population will differ (6).
Second, the mortality rates for the elderly are declining, particulariy for those over age 80 who are at highest risk for Alzheimer
disease (6,21). Third, persons with dementia are living longer;
the duration of the disease has been lengthened as medical advances in the last 30 years have delayed death from intercurrent
infections, especially pneumonia (22).
Based on this information, the task force made three recommendations. First, physicians in Michigan (and nafionwide)
should be encouraged and instmcted to include Alzheimer disease as an underlying cause of or contributor to death when
death certificates are completed. Careful and accurate completion of death certificates would yield valuable data for not only
Alzheimer disease but other conditions of concern in public
health. Second, consideration must be given to the possibility of
eventual statewide or regional surveillance of Alzheimer disease. With current diagnostic technology, the implementation of
these two recommendations would require that as many suspect
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Table 2
Predicted Number of Alzheimer Disease Cases in
Michigan, 1980 to 2040,* Using Two Prevalence Estimates
Estimated No. of Cases
Michigan Populationt
Prevalence Ratiost
Year
> age 65
4.2 (11)
11.2 (18)
1980
702,258
29,495
78,653
1985
968,259
40,667
108,445
1990
1,050,474
44,120
117,653
1995
1,100,122
46,205
123,214
2000
1,081,239
45,412
121,099
2010
1,111,997
46,704
124,544
2020
1,676,100
70,396
187,723
2030
1,863,000
78,246
208,656
2040
1,714.600
72,013
192,035
'Assumptions are that mortality rates remain constant, survival remains the same for
demented patients, and preventive and curative advances do not occur.
tPopulation figures from Michigan Department of Management and Budget. Oftice of
Revenue and Tax Analysis, 1987.
^Number of cases per 100 persons.

cases as possible undergo autopsy or at least a comprehensive
diagnosfic evaluation. Third, the state should support laboratory, clinical, and population studies of Alzheimer disease by
at least endorsing research projects, providing qualified researchers access to records, and if possible through financial
support. In terms of epidemiology, few studies have been undertaken; work is needed in both the study of risk factors and in
describing the natural history of the disease.
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